Type 1 Diabetes Honeymoon Phase

✓ Medically reviewed | Published: | Evidence level: 1A
Insulin dose-adjusted A1c (IDAA1c) is the standard tool for identifying partial remission, or the 'honeymoon phase,' in type 1 diabetes. A Baylor College of Medicine-led team reports that the score misses more than half of partial remissions in young people with overweight or obesity, likely because higher body weight and insulin resistance change how much insulin is needed. The finding suggests that a single cutoff may not fit every child.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pediatric Health

Quick Facts

IDAA1c Cutoff
9 or lower
Missed Remissions
Over half reported
Population Studied
Youth with overweight/obesity
Formula
A1c + 4 × insulin dose

What Is IDAA1c and How Is Partial Remission in Type 1 Diabetes Measured?

Quick answer: IDAA1c combines hemoglobin A1c with daily insulin dose per kilogram of body weight to estimate how much insulin-producing capacity remains, and a value of 9 or lower is the widely used threshold for partial remission.

Soon after diagnosis, many children and adolescents with type 1 diabetes enter a period known as partial clinical remission, or the 'honeymoon phase.' During this time the surviving beta cells in the pancreas still secrete some insulin, so blood glucose is easier to control and exogenous insulin needs fall. The phase can last weeks to many months and rarely signals a cure, because the underlying autoimmune destruction of beta cells usually continues.

Because directly measuring residual insulin production (for example, with stimulated C-peptide testing) is impractical in routine care, clinicians and researchers rely on IDAA1c. The score is calculated as hemoglobin A1c (in percent) plus four times the total daily insulin dose in units per kilogram of body weight. A result of 9 or below is conventionally taken to indicate partial remission. The tool is popular because it uses information already collected at clinic visits, and it has been used extensively in clinical trials of therapies designed to preserve beta-cell function.

Why Might IDAA1c Miss Partial Remission in Youth With Overweight or Obesity?

Quick answer: Excess body weight is associated with insulin resistance, which raises insulin requirements even when beta cells are still producing insulin, so the score can exceed the cutoff despite genuine remission.

A Baylor College of Medicine-led team, as reported by Medical Xpress, is calling attention to how the standard IDAA1c threshold performs in young people with type 1 diabetes who also have overweight or obesity. According to the report, the score failed to identify more than half of the partial remissions in this group. The details of the underlying analysis should be read in the original publication, but the direction of the finding fits known physiology.

The IDAA1c formula treats insulin dose as a stand-in for how much residual beta-cell function a child has. In a child with obesity, however, insulin resistance can push up the dose needed to keep glucose in range, independent of beta-cell output. That inflates the score and may classify a child as 'not in remission' when meaningful endogenous insulin secretion remains. Rising rates of overweight and obesity among youth with type 1 diabetes, a population once assumed to be mostly lean, make this a practical concern rather than a niche one.

The implications are mainly for research and clinical staging. Trials of immunotherapies that aim to preserve beta cells often use remission status as an outcome or an eligibility criterion, and a score that systematically under-detects remission in heavier participants could distort results. In clinical care, recognizing remission can help families understand why insulin doses are falling and set expectations that the phase is temporary.

What Does This Mean for Families and Clinicians Managing Pediatric Type 1 Diabetes?

Quick answer: Families should not interpret a high IDAA1c as proof that no beta-cell function remains, and clinicians may need weight-adjusted thresholds or direct C-peptide testing for children with higher body weight.

For now, the IDAA1c remains a useful, convenient screening tool, but its limits matter. Clinicians may consider supplementing it with measures of residual insulin secretion, such as C-peptide, when remission status affects decisions or research eligibility. Researchers may also explore alternative cutoffs or formulas that account for body mass index or insulin sensitivity, though any new threshold would need validation in independent cohorts before adoption.

Regardless of score, standard care does not change: children with type 1 diabetes need insulin, regular glucose monitoring or continuous glucose monitoring, and education on hypoglycemia and sick-day management. Guidance from the American Diabetes Association and the International Society for Pediatric and Adolescent Diabetes (ISPAD) also emphasizes screening for weight-related and cardiometabolic risks in young people with type 1 diabetes. Families concerned about their child's remission status or weight should discuss individualized targets with their pediatric endocrinology team rather than relying on a single number.

Frequently Asked Questions

It is a period of partial remission soon after diagnosis in which the pancreas still makes some insulin, so blood sugar is easier to control and insulin doses are often lower. It is temporary and is not a cure.

IDAA1c equals hemoglobin A1c (%) plus 4 times the total daily insulin dose in units per kilogram of body weight. A value of 9 or lower is commonly used to define partial remission.

Yes, according to the Baylor-led team's reported findings, the standard score may miss many such cases, likely because insulin resistance raises insulin needs. Direct testing such as C-peptide can give a clearer picture of residual beta-cell function.

No. Insulin should only be adjusted under the direction of the diabetes care team. Stopping insulin in type 1 diabetes can lead to diabetic ketoacidosis, which is a medical emergency.

References

  1. Medical Xpress. Common type 1 diabetes score misses over half of partial remissions in youth with overweight or obesity. November 2026.
  2. American Diabetes Association. Standards of Care in Diabetes: Children and Adolescents.
  3. International Society for Pediatric and Adolescent Diabetes (ISPAD). Clinical Practice Consensus Guidelines.